Fripnit 300 mg Tablet
PDF Leaflet Revision Date: 24 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of latent tuberculosis infection in high-risk patients.
Dosage (summary)
Once weekly for 12 weeks, max 900 mg based on weight.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; safety in lactation not established.
Key Drug Interactions
- CYP3A4 inducers/inhibitors
- Hormonal contraceptives
- Digoxin
Contraindications
- Hypersensitivity to rifapentine
- Porphyria
- Liver disease
Common side effects
- Hypersensitivity
- Nausea
- Headache
- Hepatitis
Counselling Points
- Take with food
- Monitor for liver function
- May discolor body fluids
Serious warnings
- Hepatotoxicity
- Severe cutaneous adverse reactions
- Clostridium difficile-associated diarrhea
Important Disclaimer
The Fripnit 300 mg Tablet professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
